Innate Pharma Files 6-K, Reports Press Release
Ticker: IPHYF · Form: 6-K · Filed: Dec 22, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Dec 22, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, press-release
TL;DR
Innate Pharma dropped a 6-K on 12/22/25 with a press release – check it for news.
AI Summary
Innate Pharma SA filed a Form 6-K on December 22, 2025, reporting a press release dated December 22, 2025. The filing does not contain specific financial figures or operational details beyond the reporting of this press release.
Why It Matters
This filing indicates Innate Pharma is providing an update to the market via a press release, which may contain material information about the company's operations or strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of a press release and does not contain specific financial or operational risks.
Key Players & Entities
- Innate Pharma SA (company) — Filer of the 6-K report
- December 22, 2025 (date) — Date of the report and press release
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release issued by Innate Pharma SA on December 22, 2025.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is December 22, 2025.
Does Innate Pharma file annual reports under Form 20-F or Form 40-F?
Innate Pharma indicates it files annual reports under Form 20-F.
Where is Innate Pharma SA's principal executive office located?
Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is listed in the filing?
Exhibit 99.1 is listed, described as a Press Release dated December 22, 2025.
Filing Stats: 159 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-12-22 06:08:57
Filing Documents
- a251222_6k-iphx251222.htm (6-K) — 8KB
- a251222_exhibit991.htm (EX-99.1) — 15KB
- 0001628280-25-058386.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date December 22, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive Officer